Summary of Significant Accounting Policies (Tables)

3 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Summary of Significant Customer Information

Significant customer information is as follows:

	June 30,			March 31,
	2021			2021
Percentage of accounts receivable:
Customer C		95	%		35	%
Customer D		0	%		40	%

	Three Months Ended June 30,
	2021			2020
Percentage of revenue:
Customer C		14	%		13	%
Customer B		19	%		25	%

Summary Of Revenue By Category

The following table presents revenue by category:

	Three Months Ended June 30,
	2021					2020
	Amount		Percentage of Revenue			Amount		Percentage of Revenue
	(in thousands, except percentages)
Consumer services	$	47,850		81	%	$	34,730		72	%
Research services		11,389		19	%		13,279		28	%
Therapeutics		—		0	%		48		0	%
Total	$	59,239		100	%	$	48,057		100	%

Summary of Revenue by Region based on the Shipping Address of Customers

The following table summarizes revenue by region based on the shipping address of customers or the location where the services are delivered:

	Three Months Ended June 30,
	2021					2020
	Amount		Percentage of Revenue			Amount		Percentage of Revenue
	(in thousands, except percentages)
United States	$	40,352		68	%	$	32,360		67	%
United Kingdom		13,906		23	%		13,215		28	%
Canada		3,240		6	%		1,609		3	%
Other regions		1,741		3	%		873		2	%
International		18,887		32	%		15,697		33	%
Total	$	59,239		100	%	$	48,057		100	%

Schedule Of Company Revenue and Adjusted EBITDA by Segment

The Company’s revenue and Adjusted EBITDA by segment is as follows:

	Three Months Ended June 30,
	2021			2020
	(in thousands)
Segment Revenue
Consumer and Research Services	$	59,239		$	48,009
Therapeutics		—			48
Total Revenue	$	59,239		$	48,057
Segment adjusted EBITDA
Consumer and Research Services adjusted EBITDA	$	(505	)	$	(4,236	)
Therapeutics Adjusted EBITDA		(18,303	)		(9,394	)
Unallocated Corporate		(8,467	)		(6,199	)
Total adjusted EBITDA	$	(27,275	)	$	(19,829	)
Reconciliation of net loss to adjusted EBITDA
Net Loss	$	(42,026	)	$	(35,770	)
Adjustments
Interest (income), net		(44	)		(74	)
Other (income) / expense, net		520			(878	)
Depreciation and amortization		4,638			5,532
Stock-based compensation expense		9,637			11,361
Total adjusted EBITDA	$	(27,275	)	$	(19,829	)

Summary of Customers Accounting for 10% or More of Segment Revenues

Customers accounting for 10% or more of segment revenues were as follows:

	Three Months Ended June 30,
	2021				2020
	(in thousands, except percentages)
Consumer and Research Services Segment Revenue:
Customer C(1)	$	8,512	14	%	$	5,847	12	%
Customer B(2)	$	11,209	19	%	$	11,827	25	%
Therapeutics Segment Revenue:
Customer E(2)	$	—	0	%	$	48	100	%

(1)Customer C revenues are primarily in the United States.

(2)Customer B revenues are in the United Kingdom and Customer E is in a region other than the United States, United Kingdom or Canada.